Aprepitant

Evidence Level: L5

Predicted Indications: 10

Aprepitant

Pharmacist Assessment Report

One-Sentence Summary

Aprepitant is an NK1 receptor antagonist marketed in India in several oral and injectable products. The approved indication text was not available in the data compiled for this report. The TxGNN model predicts it may be effective for nephrogenic syndrome of inappropriate antidiuresis, but no clinical trials and no relevant publications currently support this prediction. It is a model-only prediction.

Quick Overview

Item	Content
Original Indication	Not available in the compiled data (aprepitant is generally known as an antiemetic)
Predicted New Indication	Nephrogenic syndrome of inappropriate antidiuresis
TxGNN Prediction Score	0.9997
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, aprepitant is an NK1 receptor antagonist, which blocks substance P signaling. Its efficacy in its established antiemetic use is well known, but it is unclear whether this mechanism applies to the new indication.

Substance P/NK1 signaling has been loosely linked to fluid and vasopressin regulation. However, nephrogenic syndrome of inappropriate antidiuresis is caused by gain-of-function mutations in the V2 vasopressin receptor, and no established mechanistic link to NK1 antagonism exists. The high score (0.9997) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It should not be read as evidence of efficacy.

Other top-ranked predictions (for example hypertrichosis, pulmonary hypertension, leprosy and subarachnoid hemorrhage) also have no supporting clinical evidence. Subarachnoid hemorrhage has a biologically plausible but unvalidated preclinical hypothesis (substance P/NK1 involvement in blood-brain barrier disruption and cerebral edema).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the predicted indication.

India Market Information

Twenty valid single-ingredient registrations were found. Approved indication text was not available for any of them. The five main ones are listed below.

Authorization Number	Product Name	Dosage Form	Manufacturer
73901	Emend 125mg/80mg Capsule	Strip of 3 capsules	MSD Pharmaceuticals Pvt Ltd
74628	Emvoid 125 mg/80 mg Capsule	Strip of 3 capsules	Torrent Pharmaceuticals Ltd
75079	Emvoid Injection	Vial of 1 injection	Torrent Pharmaceuticals Ltd
421	Aprecap 125/80 Capsule	Strip of 3 capsules	Glenmark Pharmaceuticals Ltd
7557	Aprepit Kit	Packet of 1 kit	Cipla Ltd

Other registered products include fosaprepitant injections and tablets, and multiple kit presentations from Alkem, Sun, Intas, Abbott, Lupin, Hetero and others.

Cytotoxicity

Aprepitant is a supportive-care antiemetic, not an antineoplastic agent, so this section does not apply.

Safety Considerations

Contraindications (knowledge graph, not label text): The TxGNN knowledge graph lists a contraindication association with liver failure.
Drug Interactions: 469 interactions were identified. The examples below come from the compiled sample:
- Major: Fentanyl, Alfentanil, Acalabrutinib
- Moderate: Paclitaxel, Abemaciclib, Nifedipine, Ibuprofen, Levonorgestrel, Hydrocortisone, Rabeprazole, Fluvoxamine, Fosphenytoin, Gefitinib, among others
- Minor: Dolutegravir

Package insert warnings and contraindications were not available. Please refer to the package insert for complete safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a model score. There are no clinical trials or relevant publications, and no plausible link between NK1 antagonism and the V2 receptor gain-of-function mechanism of this disease. The single literature record matched to another prediction (pulmonary hypertension) concerns an unrelated drug and is not evidence.

To proceed, the following is needed:

Package insert warnings and contraindications from the India regulatory source (currently blocking safety screening)
Mechanism of action data (for example from DrugBank)
Preclinical evidence of NK1/substance P involvement in this disease
A review of the knowledge-graph liver failure contraindication
A target-population assessment, since this is an ultra-rare disease, and a review of the interaction burden for likely co-medications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.